Mortality among Adults with Cancer undergoing Chemotherapy or Immunotherapy Infected with COVID-19

UKCCMP Team; Lennard YW Lee DPhil; Rachel Kerr; Gary Middleton; Jean-Baptiste Cazier; Peter S Hall

doi:10.1001/jamanetworkopen.2022.0130

Mortality among Adults with Cancer undergoing Chemotherapy or Immunotherapy Infected with COVID-19

UKCCMP Team, Lennard YW Lee DPhil, Rachel Kerr, Gary Middleton^*, Jean-Baptiste Cazier, Peter S Hall

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	JAMA Network Open
DOIs	https://doi.org/10.1001/jamanetworkopen.2022.0130
Publication status	Published - 21 Feb 2022

Access to Document

10.1001/jamanetworkopen.2022.0130

vrnai_2022_oi_220011_1644548912.0317
Open Access: This is an open access article distributed under the terms of the CC-BY License.©2022 Várnai C et al. JAMA Network Open.
Final published version, 900 KBLicence: Creative Commons: Attribution (CC-BY)

Cite this

@article{69da5593aee142248f1f88a8a3eae071,

title = "Mortality among Adults with Cancer undergoing Chemotherapy or Immunotherapy Infected with COVID-19",

author = "{UKCCMP Team} and Csilla V{\'a}rnai and Claire Palles and Roland Arnold and {M Curley}, Helen and Karin Purshouse and {WT Cheng Dphil}, Vinton and Stephen Booth and {A Campton}, Naomi and {P Collins}, Graham and {J Hughes}, Daniel and {J Kulasekararaj}, Austin and {JX Lee}, Alvin and {C Olsson-Brown}, Anna and Archana Sharma-Oates and {Van Hemelrijck}, Mieke and {YW Lee DPhil}, Lennard and Rachel Kerr and Gary Middleton and Jean-Baptiste Cazier and Hall, {Peter S}",

note = "Funding Information: Funding/Support: The work was supported by University of Birmingham, University of Oxford, Blood Cancer UK (grant No. 20011), Cancer Research UK (grant No. C17422/A25154), and Bowel Cancer UK (grant No. 18PG0010). Funding Information: Conflict of Interest Disclosures: Dr Palles reported receiving grants from Blood Cancer UK and Bowel Cancer UK during the conduct of the study. Dr Arnold reported receiving grants from Blood Cancer UK during the conduct of the study. Dr Curley reported receiving grants from Blood Cancer UK during the conduct of the study. Dr Purshouse reported receiving a fellowship from the Wellcome Trust during the conduct of the study. Dr Hughes reported received research funding from Nanomab Technology, personal fees from Pfizer, and speakers{\textquoteright} fees from Novartis outside the submitted work. Dr Olsson-Brown reported receiving grant support from Roche, Bristol Myers Squibb, Eli Lilly and Co, Novartis, and UCB Pharma and receiving personal fees from Roche, Merck Sharpe and Dohme, Eisai, and Bristol Myers Squibb outside the submitted work. Prof Middleton reported receiving personal fees from Bristol Myers Squibb, Servier, Roche, Merck Sharpe and Dohme, AstraZeneca, Pfizer, and D2G outside the submitted work. Prof Cazier reported grants from Blood Cancer UK during the conduct of the study. No other disclosures were reported. Publisher Copyright: {\textcopyright} 2022 American Medical Association. All rights reserved.",

year = "2022",

month = feb,

day = "21",

doi = "10.1001/jamanetworkopen.2022.0130",

language = "English",

journal = "JAMA Network Open",

issn = "2574-3805",

publisher = "American Medical Association",

}

TY - JOUR

T1 - Mortality among Adults with Cancer undergoing Chemotherapy or Immunotherapy Infected with COVID-19

AU - UKCCMP Team

AU - Várnai, Csilla

AU - Palles, Claire

AU - Arnold, Roland

AU - M Curley, Helen

AU - Purshouse, Karin

AU - WT Cheng Dphil, Vinton

AU - Booth, Stephen

AU - A Campton, Naomi

AU - P Collins, Graham

AU - J Hughes, Daniel

AU - J Kulasekararaj, Austin

AU - JX Lee, Alvin

AU - C Olsson-Brown, Anna

AU - Sharma-Oates, Archana

AU - Van Hemelrijck, Mieke

AU - YW Lee DPhil, Lennard

AU - Kerr, Rachel

AU - Middleton, Gary

AU - Cazier, Jean-Baptiste

AU - Hall, Peter S

N1 - Funding Information: Funding/Support: The work was supported by University of Birmingham, University of Oxford, Blood Cancer UK (grant No. 20011), Cancer Research UK (grant No. C17422/A25154), and Bowel Cancer UK (grant No. 18PG0010). Funding Information: Conflict of Interest Disclosures: Dr Palles reported receiving grants from Blood Cancer UK and Bowel Cancer UK during the conduct of the study. Dr Arnold reported receiving grants from Blood Cancer UK during the conduct of the study. Dr Curley reported receiving grants from Blood Cancer UK during the conduct of the study. Dr Purshouse reported receiving a fellowship from the Wellcome Trust during the conduct of the study. Dr Hughes reported received research funding from Nanomab Technology, personal fees from Pfizer, and speakers’ fees from Novartis outside the submitted work. Dr Olsson-Brown reported receiving grant support from Roche, Bristol Myers Squibb, Eli Lilly and Co, Novartis, and UCB Pharma and receiving personal fees from Roche, Merck Sharpe and Dohme, Eisai, and Bristol Myers Squibb outside the submitted work. Prof Middleton reported receiving personal fees from Bristol Myers Squibb, Servier, Roche, Merck Sharpe and Dohme, AstraZeneca, Pfizer, and D2G outside the submitted work. Prof Cazier reported grants from Blood Cancer UK during the conduct of the study. No other disclosures were reported. Publisher Copyright: © 2022 American Medical Association. All rights reserved.

PY - 2022/2/21

Y1 - 2022/2/21

U2 - 10.1001/jamanetworkopen.2022.0130

DO - 10.1001/jamanetworkopen.2022.0130

M3 - Article

SN - 2574-3805

JO - JAMA Network Open

JF - JAMA Network Open

ER -